Tag:

Depression

Health

Covid long: Bacteria in nose could predict & prevent long-term symptoms

by Chief Editor
written by Chief Editor

The Emerging Link Between Gut Bacteria and Long COVID Recovery

For many, the battle against COVID-19 doesn’t end with a negative test. Long COVID, characterized by persistent symptoms like fatigue, brain fog, and respiratory issues, continues to affect millions. While the exact causes remain elusive, a growing body of research points to a surprising player: the microbiome, specifically the bacteria residing in our respiratory system.

A Bacterial Imbalance and Persistent Inflammation

Recent studies, including research from the UCLouvain and Cliniques universitaires Saint-Luc in Belgium, have identified a potential link between the abundance of certain gut bacteria and the development of Long COVID. Researchers discovered that individuals who went on to develop Long COVID had lower levels of Dolosigranulum pigrum, a bacterium naturally found in the respiratory microbiome, during the acute phase of infection. This suggests that a disruption in the delicate balance of these microbial communities could play a role in the persistence of symptoms.

This finding aligns with broader research indicating that Long COVID is often characterized by persistent inflammation. Inflammation after SARS-CoV-2 infections has been shown to cause damage to organs like the lungs and kidneys, and even affect brain function, as demonstrated in studies on hamsters. The Harvard Gazette reported that those with the greatest inflammation at the start of infection were more likely to experience lingering symptoms, suggesting the initial immune response can, in some cases, set the stage for Long COVID.

The Role of the Microbiome in Immune Response

The connection between gut bacteria and immune function is well-established. The microbiome influences the development and regulation of the immune system, and imbalances can contribute to chronic inflammation. Researchers hypothesize that Dolosigranulum pigrum may play a protective role by modulating the immune response and preventing excessive inflammation. A disrupted microbiome could therefore leave individuals more vulnerable to the long-term effects of COVID-19.

This isn’t an isolated observation. Studies have shown that Long COVID involves activation of proinflammatory and immune responses, with upregulation of pathways related to inflammation and immune dysfunction. The Nature article highlights that these persistent immune activations are observed even 18 months after initial infection.

Potential Therapeutic Strategies: Restoring Microbial Balance

The identification of Dolosigranulum pigrum as a potential protective bacterium opens up exciting possibilities for therapeutic intervention. One promising avenue is the development of targeted therapies aimed at restoring microbial balance in the respiratory system. This could involve:

  • Probiotic Sprays: Nasal sprays containing Dolosigranulum pigrum or other beneficial bacteria could facilitate colonize the respiratory tract and bolster the immune response.
  • Prebiotic Interventions: Dietary or supplemental prebiotics could nourish existing beneficial bacteria and promote their growth.
  • Fecal Microbiota Transplantation (FMT): While more invasive, FMT – transferring fecal matter from a healthy donor to a recipient – is being explored as a potential treatment for various microbiome-related conditions.

However, researchers caution that these approaches are still in the early stages of development. Further research is needed to understand the precise mechanisms by which Dolosigranulum pigrum exerts its protective effects and to ensure the safety and efficacy of any interventions.

The Importance of Responsible Antibiotic Use

The study similarly underscores the importance of responsible antibiotic use. Antibiotics, while essential for treating bacterial infections, can disrupt the microbiome, potentially eliminating beneficial bacteria like Dolosigranulum pigrum. This disruption could increase susceptibility to Long COVID or exacerbate existing symptoms.

Pro Tip: Avoid unnecessary antibiotic use. Consult with your doctor to determine if antibiotics are truly needed for your condition.

Future Research Directions

The research community is actively pursuing several key areas of investigation:

  • Understanding the Mechanisms: Researchers are working to unravel the precise mechanisms by which Dolosigranulum pigrum protects against Long COVID.
  • Identifying Other Key Bacteria: Identifying other bacterial species that may contribute to or protect against Long COVID.
  • Developing Targeted Therapies: Developing and testing targeted therapies aimed at restoring microbial balance.
  • Personalized Medicine: Tailoring treatment strategies based on an individual’s microbiome profile.

FAQ

Q: Can I improve my gut health to prevent Long COVID?
A: While more research is needed, maintaining a healthy lifestyle with a balanced diet, regular exercise, and limited antibiotic use can support a healthy microbiome.

Q: Are probiotics a guaranteed solution for Long COVID?
A: Not at this time. Probiotics may be helpful for some individuals, but more research is needed to determine the most effective strains and dosages.

Q: Is Long COVID always caused by a bacterial imbalance?
A: No. Long COVID is a complex condition with multiple potential causes, including persistent viral reservoirs, autoimmunity, and tissue damage.

Did you know? Long COVID affects an estimated 15 million Americans, according to recent data from the U.S. Department of Health and Human Services.

Explore further: Read more about the latest research on Long COVID and the microbiome here.

Have you experienced Long COVID? Share your story and insights in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

New Tool Maps Hyperarousal Dimensions for Personalized Care

by Chief Editor
written by Chief Editor

Beyond Fight or Flight: The Future of Personalized Mental Healthcare

For decades, “hyperarousal” has been a catch-all term in mental health, describing a state of heightened alert. Now, a groundbreaking 2026 study published in eClinicalMedicine is changing that, identifying seven distinct dimensions of hyperarousal and introducing the Transdiagnostic Hyperarousal Dimensions Questionnaire (THDQ). This isn’t just about semantics; it’s a potential revolution in how we diagnose and treat conditions ranging from insomnia and anxiety to PTSD and ADHD.

Decoding the Seven Dimensions of Tension

The research reveals that hyperarousal isn’t a single entity, but a complex interplay of physiological and emotional responses. The seven dimensions identified are Anxious, Somatic, Sensitive, Sleep-related, Irritable, Vigilant, and Sudomotor (relating to sweating and facial flushing). Understanding which dimensions are dominant in a patient’s experience is key to moving beyond generalized treatments.

For example, the study highlights how generalized anxiety disorder primarily manifests along the ‘Anxious’ dimension, even as insomnia is strongly linked to ‘Sleep-related’ hyperarousal. PTSD, unsurprisingly, shows strong correlations with ‘Vigilant’ and ‘Sudomotor’ responses. This nuanced understanding allows clinicians to pinpoint the specific drivers of a patient’s distress.

The THDQ: A New Standard for Assessment

The development of the THDQ – a concise, 27-item questionnaire – provides a standardized tool for assessing these dimensions. Its reliability, demonstrated by a Cronbach’s alpha of 0.90 and consistent results over a year of testing, is a significant step forward. Previously, clinicians relied on a patchwork of surveys, leading to inconsistencies and potentially inaccurate diagnoses.

Pro Tip: Early adoption of standardized assessment tools like the THDQ can position healthcare providers at the forefront of personalized mental healthcare.

Leveraging Existing Data for Large-Scale Insights

The THDQ’s impact extends beyond individual patient care. Researchers discovered that 22 items within the questionnaire already exist in the UK Biobank, a vast database containing genetic and health information from hundreds of thousands of participants. This allows for large-scale studies linking hyperarousal traits to biological factors, paving the way for precision medicine approaches.

Personalized Treatment: Beyond One-Size-Fits-All

The implications for treatment are profound. A patient presenting with insomnia, but also exhibiting high scores in ‘Vigilant’ and ‘Sudomotor’ dimensions, might benefit from interventions addressing underlying trauma rather than solely focusing on sleep hygiene. This targeted approach promises more effective and efficient care.

recognizing the interplay between hyperarousal and physical health is crucial. Chronic sleep disruption, linked to ‘Sleep-related’ hyperarousal, has been associated with accelerated cognitive decline and an increased risk of dementia, as a 2025 study in Neurology demonstrated.

The Rise of Complementary Therapies

While pharmacological and traditional therapeutic interventions remain vital, there’s growing recognition of the benefits of low-cost complementary approaches. Journaling, for instance, has shown modest but consistent benefits in alleviating symptoms of anxiety, depression, and PTSD. Structured expressive writing and gratitude journaling can improve emotional regulation and cognitive function, particularly with consistent practice over 30 days.

Mental Health in a Post-Pandemic World: A Focus on Mexico

The necessitate for improved mental healthcare is particularly acute in the wake of the COVID-19 pandemic. In Mexico, studies indicate that 20% of the population experiences depression, with young adults and middle-aged individuals being most affected. Anxiety impacts over half of patients seeking treatment, and rates of burnout, PTSD, and substance use are also on the rise.

This has spurred increased adoption of emotional wellness programs, mental health days, and telemedicine solutions. The potential of AI-driven mental health platforms to expand access to care, particularly in areas facing workforce shortages, is also being explored.

Did you know?

Hyperarousal isn’t always a negative experience. A healthy level of arousal is essential for motivation, focus, and performance. The key is understanding when it becomes dysregulated and interferes with daily life.

Frequently Asked Questions

  • What is hyperarousal? It’s a heightened state of physiological and emotional activation, where the body’s “fight-or-flight” response is overactive.
  • What is the THDQ? The Transdiagnostic Hyperarousal Dimensions Questionnaire is a new tool for assessing the seven dimensions of hyperarousal.
  • Why is understanding the dimensions of hyperarousal vital? It allows for more personalized and effective treatment plans.
  • Can journaling really help with mental health? Yes, structured journaling can improve emotional regulation and cognitive function.

The future of mental healthcare is moving towards a more precise, personalized approach. The identification of hyperarousal dimensions and the development of tools like the THDQ are crucial steps in that direction. As research continues and technology advances, we can expect even more sophisticated methods for understanding and addressing the complex challenges of mental wellbeing.

Explore further: Read more about healthcare innovations in Mexico.

0 comments
0 FacebookTwitterPinterestEmail
Health

ADHD prescriptions surged during the COVID-19 pandemic

by Chief Editor
written by Chief Editor

The ADHD Prescription Surge: What’s Driving the Trend and What Does It Mean for the Future?

The COVID-19 pandemic dramatically reshaped healthcare access, and with it, patterns of ADHD diagnosis and treatment. A recent study published in the Canadian Medical Association Journal (CMAJ) reveals a significant surge in stimulant prescriptions for adults in Ontario, Canada, raising significant questions about evolving diagnostic practices, access to care, and the long-term implications of increased medication use.

A Pandemic-Fueled Increase in Diagnosis

Prior to 2020, adult stimulant prescriptions were steadily increasing, reflecting growing awareness of ADHD and reduced stigma surrounding mental health. However, the pandemic acted as an accelerator. The study found that the monthly rate of increase in new stimulant prescriptions after the pandemic began was 7.3 times faster than the pre-pandemic trend. By June 2024, rates reached 0.44 new stimulant dispensations for every 1,000 adults.

This increase wasn’t uniform across demographics. Young adults aged 18-34 were key drivers of the trend, with women experiencing a faster rate of prescription increases than men. In fact, by June 2024, more women than men in all age groups were starting stimulant medication.

Telehealth and Changing Prescribing Patterns

The rapid expansion of telehealth during the pandemic likely played a crucial role in this surge. Increased accessibility to virtual appointments removed barriers to diagnosis and treatment for many. However, this shift also coincided with changes in who was prescribing these medications. Although psychiatrists traditionally dominated stimulant prescriptions, the study noted a growing role for nurse practitioners.

This shift isn’t necessarily negative, but it does raise questions about consistency in diagnostic practices. The study highlights the need for careful monitoring to ensure appropriate use and avoid potential overdiagnosis.

Beyond ADHD: Co-occurring Conditions and the Rise in Anxiety

The study also examined the prevalence of co-occurring conditions among those newly prescribed stimulants. While the proportion of patients with a documented ADHD or childhood behavioral diagnosis increased from 23.8% to 31.3%, the number of patients with anxiety or depression also rose significantly – a 74% increase. This suggests that many adults seeking stimulant prescriptions may be grappling with multiple mental health challenges, potentially exacerbated by the stresses of the pandemic.

What Does the Future Hold?

The trends identified in the Ontario study are likely reflective of broader patterns across North America and beyond. Several factors suggest that the demand for ADHD diagnosis and treatment will remain high.

  • Increased Awareness: Ongoing public health campaigns and media coverage continue to raise awareness of ADHD in adults.
  • Changing Workplace Demands: The modern workplace often requires sustained attention and focus, which can be particularly challenging for individuals with undiagnosed or untreated ADHD.
  • Digital Distractions: The constant barrage of notifications and stimuli from digital devices can exacerbate ADHD symptoms.

However, addressing this growing demand requires a multifaceted approach.

The Need for Further Research

The study authors emphasize the need for continued research to better understand the long-term consequences of increased stimulant use, identify the underlying drivers of the surge in diagnoses, and develop strategies to ensure appropriate care. Specifically, research should focus on:

  • The effectiveness of telehealth-based ADHD assessments.
  • The impact of stimulant medication on long-term health outcomes.
  • Strategies to address the co-occurring mental health conditions often seen in adults with ADHD.

Frequently Asked Questions

Is the increase in ADHD diagnoses a sign of overdiagnosis?
It’s a complex question. While increased awareness and access to care are positive developments, it’s crucial to ensure that diagnoses are accurate and appropriate. Further research is needed to determine the extent to which the surge in prescriptions reflects genuine increases in prevalence versus potential overdiagnosis.
Are stimulants the only treatment option for ADHD?
No. A comprehensive treatment plan often includes therapy (such as cognitive behavioral therapy), lifestyle modifications (like exercise and a healthy diet), and educational support.
What role does telehealth play in ADHD diagnosis and treatment?
Telehealth has significantly increased access to care, particularly for individuals in rural areas or with limited mobility. However, it’s important to ensure that telehealth assessments are thorough and accurate.

The surge in ADHD prescriptions is a complex phenomenon with far-reaching implications. By continuing to monitor trends, conduct rigorous research, and prioritize patient-centered care, we can ensure that individuals with ADHD receive the support they need to thrive.

Want to learn more about ADHD and mental health? Explore our other articles on managing stress and improving focus.

0 comments
0 FacebookTwitterPinterestEmail
Health

New review reveals complex polygenic architecture underlying common epilepsies

by Chief Editor
written by Chief Editor

Unlocking the Genetic Code of Epilepsy: A New Era of Precision Medicine

Recent advances in molecular genetic research are reshaping our understanding of epilepsy, moving beyond the traditional view of a single disease to a complex constellation of seizure disorders. A new mini-review published in Genomic Psychiatry, led by Dr. Olav B. Smeland of the Centre for Precision Psychiatry at Oslo University Hospital and the University of Oslo, synthesizes decades of research, revealing a genetic landscape far more intricate than previously imagined.

From Twin Studies to Genome-Wide Analysis

The journey to unraveling the genetics of epilepsy began with twin studies in the 1930s. These early investigations demonstrated a higher concordance rate for epilepsy in identical twins compared to fraternal twins, establishing a clear heritable component. Modern genome-wide association studies (GWAS) and whole-exome sequencing projects have built upon this foundation, identifying thousands of implicated genes. However, the complexity lies in the fact that epilepsy isn’t a single genetic entity.

Different subtypes of epilepsy exhibit varying degrees of heritability. Genetic generalized epilepsy, for example, shows a significantly higher SNP-heritability compared to focal epilepsy, highlighting the importance of diagnostic precision in genetic research.

Rare Variants and Common Ground

Genetic research has followed two parallel tracks: investigating rare, high-impact genetic variants and exploring the influence of common genetic variants. Studies of severe monogenic epilepsies have identified over a thousand implicated genes. Simultaneously, research on common epilepsies, including genetic generalized epilepsy and focal epilepsy, has revealed a polygenic inheritance pattern, meaning multiple genes contribute to risk.

Interestingly, both rare and common variants are converging on shared biological pathways. Genes like DEPDC5, NPRL3, SCN1A, and SCN8A appear in both rare variant analyses and common variant association studies, pointing to shared mechanisms involving ion channel function and synaptic excitability.

The Power of Large-Scale Studies

The largest genome-wide association study of common epilepsies to date, involving nearly 30,000 cases, identified 26 genome-wide significant loci, with the majority associated with genetic generalized epilepsy. Dr. Smeland emphasizes the cost-efficiency of scaling up GWAS for genetic generalized epilepsy, suggesting that a modestly larger study could capture approximately 50% of its common genetic variance.

Did you know? The genetic architecture of generalized epilepsies offers a particularly favorable ratio of heritability to polygenicity, making it a promising area for genetic discovery.

Epilepsy and the Psychiatric Spectrum

The genetic connections extend beyond epilepsy itself. The review highlights significant genetic pleiotropy, meaning that the same genetic variants can influence multiple traits. Both focal and generalized epilepsies show genetic correlations with cognitive ability and major psychiatric disorders, including schizophrenia, major depression, bipolar disorder, and anxiety.

This overlap provides a molecular explanation for the frequently observed comorbidity between epilepsy and psychiatric conditions. Understanding these shared genetic foundations may eventually help identify epilepsy patients at elevated risk for psychiatric comorbidities.

Polygenic Risk Scores: Promise and Limitations

Polygenic risk scores (PRS), which estimate an individual’s genetic predisposition to a disease, offer a potential tool for risk stratification. A PRS for genetic generalized epilepsy can increase lifetime risk by a hazard ratio of 1.73 per standard deviation increase. However, current PRS have limited discriminative performance and are not yet ready for routine clinical use.

Pro Tip: Broadening ancestral diversity in study populations is crucial before implementing PRS for equitable healthcare.

A significant limitation is the lack of diversity in existing datasets. Over 92% of cases in the largest epilepsy GWAS are of European ancestry, limiting the generalizability of risk scores to other populations.

The Future: Multimodal Data Integration

The future of epilepsy research lies in integrating genetics with other data modalities, including clinical variables, cognitive assessments, other omics data, electronic health records, neuroimaging, and data from sensing devices. Large biobanks, such as the UK Biobank and the All of Us Research program, will serve as essential platforms for this integration.

Advancements in artificial intelligence and machine learning will be crucial for effectively analyzing these complex, multimodal datasets. The goal is to develop genuinely predictive models that can personalize treatment and improve outcomes for individuals with epilepsy.

FAQ

Q: What is SNP-heritability?
A: SNP-heritability is the fraction of phenotypic variation attributable to common genetic variants.

Q: What is genetic pleiotropy?
A: Genetic pleiotropy is when a single genetic variant influences more than one trait.

Q: Are polygenic risk scores currently used in clinical practice for epilepsy?
A: Not routinely. Although promising, current PRS have limitations and are not yet ready for widespread clinical implementation.

Q: Why is diversity in genetic studies important?
A: A lack of diversity limits the generalizability of findings and can lead to inequities in healthcare.

The research led by Dr. Smeland and his colleagues represents a significant step forward in understanding the genetic basis of epilepsy. As the field continues to evolve, the integration of genetics with other data modalities promises to unlock new avenues for diagnosis, treatment, and prevention.

Want to learn more? Explore additional resources on epilepsy genetics at the Epilepsy Foundation and the Nature Neuroscience journal.

0 comments
0 FacebookTwitterPinterestEmail
Health

Largest genetic study classifies 14 psychiatric disorders into five major groups

by Chief Editor
written by Chief Editor

Unlocking the Genetic Codes of Mental Health: A Novel Era of Diagnosis and Treatment

For decades, mental health diagnoses have relied heavily on clinical evaluation – a process often complicated by overlapping symptoms and subjective interpretations. But a groundbreaking new study, published in Nature, is poised to revolutionize our understanding of psychiatric disorders by classifying 14 conditions into five major genetic groups. This isn’t about finding a single “gene for depression” or “gene for schizophrenia,” but rather recognizing shared biological underpinnings that can reshape how we approach prevention, diagnosis and treatment.

The Five Genetic Factors: What the Study Revealed

Researchers analyzed common genetic variations – single nucleotide polymorphisms (SNPs) – across a massive dataset of over one million individuals, both with and without psychiatric conditions. The analysis revealed five distinct factors:

  • Factor 1: Compulsive Behaviors – Encompassing anorexia nervosa, obsessive-compulsive disorder (OCD), Tourette syndrome, and anxiety disorders.
  • Factor 2: Psychotic Disorders – Primarily defined by schizophrenia and bipolar disorder, sharing genetic links in brain regions responsible for processing reality.
  • Factor 3: Neurodevelopmental Conditions – Including autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), and, to a lesser extent, Tourette syndrome.
  • Factor 4: Internalizing Disorders – Characterized by depression, anxiety disorders, and post-traumatic stress disorder (PTSD), with genetic links to brain support cells (glia) rather than neurons.
  • Factor 5: Substance Use Disorders – Covering alcohol use disorder, nicotine dependence, cannabis use disorder, and opioid use disorder, and showing a stronger association with socioeconomic factors.

Interestingly, Tourette syndrome appears to be genetically distinct, with 87% of its genetic characteristics being unique among the disorders studied. The study too identified a “P factor” – genetic variants present across all 14 conditions, suggesting a common underlying vulnerability.

Drug Repurposing and the Future of Treatment

One of the most promising implications of this research lies in the potential for drug repurposing. If conditions share genetic pathways, a drug already approved for one disorder might prove effective for another. This approach can significantly accelerate the development of new treatments, bypassing lengthy and expensive clinical trials. Researchers are already exploring this possibility.

“Our genome has rare and common genetic variants. This study looked only at the common ones…This is a category of variants with a major impact on multifactorial diseases, such as psychiatric conditions,” explains Sintia Belangero, a professor at the São Paulo School of Medicine.

Addressing the Diversity Gap in Genomic Research

Even as this study represents a significant leap forward, researchers acknowledge a critical limitation: the disproportionate representation of individuals of European ancestry in genomic datasets. This bias can limit the generalizability of findings to other populations. However, initiatives like the Latin American Genomics Consortium (LAGC) are actively working to address this gap by collecting genomic data from diverse populations, including those in Brazil, to ensure more equitable and inclusive research.

Did you know? Approximately half of the world’s population will experience a mental disorder during their lifetime.

Beyond Biology: The Intersection of Genes and Environment

The study highlights that psychiatric disorders aren’t solely determined by genetics. The interplay between genetic predisposition and environmental factors – life experiences, socioeconomic conditions, and social support – is crucial. As Abdel Abdellaoui, a professor at the University of Amsterdam, notes, these disorders often arise at the extremes of natural genetic variation when combined with unfavorable life circumstances. This reframes mental illness not as a biological defect, but as a complex interaction between inherent traits and external stressors.

Frequently Asked Questions (FAQ)

Q: Does this mean we’ll have a genetic test for mental illness soon?
A: Not immediately. This research identifies genetic factors associated with risk, but it doesn’t provide a single gene that definitively predicts whether someone will develop a disorder.

Q: Will this change how I’m treated if I have a mental health condition?
A: It’s unlikely to have an immediate impact on your current treatment. However, it lays the groundwork for more targeted and effective therapies in the future.

Q: Why is diversity in genetic research important?
A: Genetic variations differ across populations. Research based on limited populations may not accurately reflect the experiences of everyone.

Q: What is a genome-wide association study (GWAS)?
A: A GWAS is a method used to identify genetic variations associated with a particular trait or disease by examining the entire genome.

Pro Tip: Focus on building resilience through healthy lifestyle choices – diet, exercise, sleep, and social connection – to mitigate the impact of genetic vulnerabilities.

This research marks a pivotal moment in the field of mental health. By unraveling the genetic complexities of these conditions, we are paving the way for a future where diagnosis is more precise, treatments are more effective, and individuals receive the personalized care they deserve.

Want to learn more? Explore additional resources on psychiatric genomics at the Nature website and the São Paulo Research Foundation (FAPESP).

0 comments
0 FacebookTwitterPinterestEmail
Health

Scientists call for integration of physical activity into psychiatric care

by Chief Editor
written by Chief Editor

Mental Health & Movement: A Modern Prescription for a Longer Life

For decades, the focus of mental healthcare has centered on medication and therapy. But a growing body of evidence, culminating in a recent review published in JAMA Psychiatry, suggests a critical component has been missing: physical activity. Scientists led by the Medical University of Vienna are now urgently calling for exercise to be recognized as an integral part of psychiatric treatment, a shift that could dramatically improve the lives – and lifespans – of millions.

The Silent Epidemic of Premature Mortality

People living with mental illnesses like schizophrenia, depression, and bipolar disorder face a stark reality: they die, on average, 10 to 20 years earlier than the general population. This isn’t due to their mental health condition directly, but rather the significant increase in cardiovascular and metabolic diseases that often accompany these illnesses. A lack of exercise is a major contributing factor.

Consider this: individuals with schizophrenia spend, on average, almost ten hours a day sedentary – more than almost any other demographic group. Less than 20% meet the World Health Organization’s (WHO) recommendations of at least 150 minutes of moderate or 75 minutes of vigorous physical activity per week. Those with depression or bipolar disorder are up to 50% less likely to be sufficiently active compared to their peers.

Exercise: More Than Just a Symptom Fix

The connection between mental health and physical activity isn’t simply about alleviating symptoms. Research reveals a complex interplay of biological mechanisms. Lack of exercise disrupts the body’s stress hormone system (HPA axis), increases inflammation, impairs dopamine reward circuits, and reduces levels of BDNF – a crucial protein for brain health and mood regulation. Fortunately, exercise actively reverses these processes.

“The drastically reduced life expectancy of people with severe mental illness is one of the most shameful inequalities in modern medicine,” says Brendon Stubbs, lead author of the JAMA Psychiatry review and researcher at the Medical University of Vienna. “Exercise is not a panacea, but it is a proven, universally accessible and cost-effective tool that can really help reduce this inequality.”

The 5A Model: Integrating Exercise into Care

The challenge isn’t proving exercise *works*; it’s systematically integrating it into psychiatric care. The review proposes a practical solution: the 5A model – Ask, Assess, Advise, Assist, and Arrange. This framework empowers any mental health professional to:

  • Ask about a patient’s activity level.
  • Assess their readiness to change.
  • Advise on personalized exercise recommendations.
  • Assist with motivation and goal setting.
  • Arrange follow-up appointments to track progress.

This approach transforms exercise from an afterthought into a standard component of treatment, much like medication or psychotherapy.

Future Trends: Personalized Exercise & Technology

Looking ahead, several trends promise to further enhance the integration of physical activity into mental healthcare.

Personalized Exercise Prescriptions: Moving beyond generic recommendations, future care will likely involve tailored exercise plans based on an individual’s diagnosis, symptom severity, physical capabilities, and personal preferences. This could involve wearable technology to monitor activity levels and provide real-time feedback.

Digital Therapeutics: Apps and online platforms offering guided exercise programs specifically designed for individuals with mental health conditions are poised to become more prevalent. These tools can provide accessibility and convenience, particularly for those facing barriers to traditional exercise settings.

Group Exercise & Social Connection: Recognizing the social benefits of exercise, group programs and peer support initiatives will likely expand. These initiatives address both physical and emotional well-being, fostering a sense of community and reducing feelings of isolation.

Focus on Cardiometabolic Health: Increased awareness of the link between mental illness and cardiovascular/metabolic disease will drive a more holistic approach to care, with exercise playing a central role in preventative strategies.

Did you recognize? Structured exercise can lead to moderate to large improvements in depression, psychotic symptoms, cognitive performance, quality of life, and cardiometabolic health.

FAQ

Q: Is exercise a replacement for medication or therapy?
A: No. Exercise is a complementary therapy that should be used *in conjunction* with existing treatments, not as a replacement.

Q: What kind of exercise is best?
A: The best exercise is the one you enjoy and will stick with. It could be walking, running, swimming, dancing, yoga, or anything else that gets you moving.

Q: How much exercise is enough?
A: The WHO recommends at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity aerobic activity per week.

Q: I have severe mental illness and struggle with motivation. Where do I start?
A: Start tiny. Even a 10-minute walk can be beneficial. Talk to your healthcare provider about developing a personalized exercise plan.

Pro Tip: Find an exercise buddy for accountability and support. Social connection can craft exercise more enjoyable and sustainable.

This shift towards prioritizing physical activity in mental healthcare represents a significant opportunity to improve the lives of millions. It’s a reminder that true well-being encompasses both the mind and the body.

What are your thoughts on integrating exercise into mental healthcare? Share your experiences and ideas in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Healing From Depression Doesn’t Always Feel Good — 10 Signs You’re Actually Getting Better

by Chief Editor
written by Chief Editor

The Unexpected Aftermath of ‘Heated Rivalry’ and the Rise of Parasocial Grief

You’ve spent the last couple of weeks in hiding, becoming a recluse. You spent your days sleeping, eating junk, and binge-watching the entire series of Heated Rivalry or Bridgerton. But now, as you climb out of the darkness, things are finally seeming more stable. Healing from depression isn’t easy, but it’s possible. And as you work your way back, you might notice subtle shifts – signs you’re actually getting better.

The ‘Heated Rivalry’ Effect: More Than Just a Show

The popularity of Rachel Reid’s “Heated Rivalry” and its television adaptation has sparked a surprising phenomenon: a wave of intense emotional responses, even depressive episodes, among fans. The show, following the complex relationship between hockey players Shane Hollander and Ilya Rozanov, has resonated deeply, particularly with women. This isn’t simply enjoyment; it’s something more profound.

A November 2025 study published in Acta Psychologica explored this phenomenon, recognizing the need for scientific explanation for the melancholy many fans are experiencing. Fans report feeling a sense of loss and emptiness after finishing the series, a feeling that extends beyond typical enjoyment of a show.

10 Signs You’re Actually Getting Better (Even When It Doesn’t Feel Like It)

1. Your Sleep Patterns Are Resetting

After weeks of disrupted sleep, your body is attempting to recalibrate. You may still nap, but those naps leave you feeling energized, and you’re finding it easier to stay awake later. Sleep disturbance is a significant symptom of depression, and changes in sleep patterns can signal recovery.

2. Reconnecting with Friends

A study by Massachusetts General Hospital found that social connection is the single strongest protective factor against depression. That urge to reach out to friends, to text and check in, isn’t clinginess; it’s your brain seeking the support it needs.

3. Mood Swings, But Less Overwhelming

Recovery isn’t linear. You might still experience sudden tears, anger, or anxiety, but these moments feel less all-consuming. Licensed professional counselor Brittney Lindstrom explains that during recovery, you may feel guilty for experiencing good things while still feeling sad.

4. Appetite Stabilization

The appetite swings common during depression are driven by neurological pathways. As you recover, those systems are rebooting, and your appetite may feel erratic before finding its balance.

5. Rediscovering Joyful Activities

You’re starting to seek out things that once brought you pleasure, even if it’s just window shopping or starting a latest hobby. Licensed clinical social worker Cheryl Gerson states that joyful music raises the spirits and distracts the mind from overthinking.

6. Peaceful Solitude

Being alone can be dangerous during recovery, but you’re finding that solitude feels peaceful, not isolating. Maintaining social connections is crucial, as research shows it protects against future depression.

7. Truly Feeling Music Again

Music isn’t just something you hear; it’s something you feel. It’s a way to regulate emotions and give your feelings a voice when your brain struggles to articulate them.

8. Small Splurges as Self-Care

Retail therapy is real. A study in the Journal of Consumer Psychology found that making purchase decisions can reduce sadness by restoring a sense of control.

9. A Sense of Future Possibility

You’re starting to glance forward, picking up new hobbies or revisiting aged ones. Therapist Miki Anderson advises that engaging in pleasurable activities can provide structure and improve mood during recovery.

10. Tending to Your Space

Depression often leads to neglecting your surroundings. The urge to clean and organize is a sign that you’re regaining control and self-care.

The Link to ‘The Long Game’ and Continued Investment

For fans of “Heated Rivalry,” the story doesn’t finish with the first season. Rachel Reid’s sequel, “The Long Game,” continues Shane and Ilya’s journey. The show’s ending closely aligns with the book’s, leaving fans eager for the second season. Ilya experiences severe depression in the sequel and pursues therapy, though initially keeps it from Shane.

The Broader Trend: Emotional Investment in Fictional Worlds

“Heated Rivalry” isn’t an isolated case. Similar reactions have been reported after finishing shows like “Bridgerton” and “The Summer I Turned Pretty.” This suggests a growing trend of intense emotional investment in fictional worlds and characters, particularly within the romance genre. The show’s stars, Hudson Williams and Connor Storrie, have even become public figures, presenting at the Golden Globes and serving as torchbearers for the Winter Olympics.

FAQ: Navigating Emotional Responses to Fictional Content

  • Is it normal to feel sad after finishing a show? Yes, it’s common to experience a sense of loss, but intense or prolonged sadness could indicate a deeper emotional response.
  • What can I do if a show is triggering depressive feelings? Reach out to friends, family, or a mental health professional. Limit your exposure to the show and engage in self-care activities.
  • Is this related to parasocial relationships? While related, the responses to “Heated Rivalry” seem to go beyond typical parasocial grief, potentially triggering or exacerbating existing vulnerabilities.

If you are struggling with depression, please reach out for help. You are not alone.

0 comments
0 FacebookTwitterPinterestEmail
Health

Plant called ‘nature’s Valium’ can help with anxiety, stress, insomnia

by Chief Editor
written by Chief Editor

Ancient Remedy, Modern Appeal: Why Valerian Root is Having a Moment

Modern science is beginning to validate what traditional healers have understood for centuries. As rates of anxiety and sleep disorders climb, more people are turning to natural remedies – and valerian root, with a history stretching back to ancient Greece and Rome, is experiencing a surge in popularity.

Although pharmaceuticals are newer, valerian root has been used as a sedative since ancient Greek and Roman times. wollertz – stock.adobe.com

A History Rooted in Tradition

Valerian (Valeriana officinalis) is a flowering plant native to Europe and southwestern Asia. Its use as a medicinal herb dates back to ancient Greece and Rome, with Hippocrates and Galen both prescribing it for sleep disturbances. Throughout history, it’s been used for everything from stress relief during World War II air raids to easing menstrual cramps.

How Does Valerian Work?

The plant grows up to 6 feet tall and supplements are typically made from the dried, crushed roots, available in capsules, powders, or teas. While the exact mechanisms aren’t fully understood, research suggests valerian impacts gamma-aminobutyric acid (GABA) receptors in the brain – a natural nerve regulator. GABA also plays a role in managing premenstrual syndrome symptoms.

The Rise of Natural Alternatives

The global valerian root powder market is projected to exceed $1 billion in value by 2034, reflecting a growing consumer interest in natural alternatives to synthetic drugs. This trend is fueled by rising rates of anxiety, stress, sleep imbalance, and mental health disorders. However, the US Food and Drug Administration has not approved the supplement, and its effectiveness can vary.

Tiny white Valeriana microphylla flowers in bloom.
0 comments
0 FacebookTwitterPinterestEmail
Business

Young woman testifies against social media giants over technology addiction

by Chief Editor
written by Chief Editor

Social Media on Trial: A Generation’s Mental Health Under Scrutiny

Los Angeles is currently the epicenter of a landmark legal battle that could reshape the future of social media. A 20-year-classic woman, identified as KGM, is suing Meta (parent company of Instagram and Facebook) and Google (owner of YouTube), alleging that the platforms were deliberately designed to be addictive, contributing to her depression and suicidal thoughts. This case, along with two others, is a “bellwether trial,” meaning its outcome could significantly influence thousands of similar lawsuits.

The Plaintiff’s Testimony: A Childhood Lived Online

KGM began using YouTube at age six and Instagram at age nine. Her testimony reveals a childhood deeply intertwined with social media, where notifications provided a “rush” and she actively sought validation through likes and filters. She described setting up multiple accounts to maximize engagement and even purchasing likes to appear more popular. The case highlights the allure of these platforms for young users and the potential for compulsive behavior.

The Role of Filters and Body Image

A key element of the plaintiff’s experience centers around Instagram filters, which she used on “almost all” of her photos. KGM testified that she didn’t experience negative feelings about her body image before using social media and filters, suggesting a potential link between platform use and the development of body dysmorphia. This resonates with growing concerns about the impact of curated online personas on self-esteem, particularly among young people.

Defense Strategies: Blaming Home Life and Pre-Existing Conditions

Meta and YouTube’s defense hinges on the argument that KGM’s mental health struggles stemmed from pre-existing issues and a “turbulent home life.” Attorneys presented text exchanges and videos depicting challenging interactions with her mother, attempting to demonstrate that the platforms were a coping mechanism rather than the root cause of her distress. During cross-examination, KGM acknowledged that her mother was physically and emotionally abusive during a period of self-harm in the 6th grade, but also stated she doesn’t currently label those actions as abuse or neglect.

Contradictions in Testimony

The defense highlighted discrepancies between KGM’s current testimony and statements made in a prior deposition. These contradictions centered on the impact of various experiences on her mental health, raising questions about the consistency of her account. KGM explained that she may have “misspoke at times” during the earlier deposition.

The Broader Legal Landscape and Future Implications

This trial is one of many targeting social media companies, alleging addictive design and harm to young users. The outcome could set a precedent for how these platforms are regulated and held accountable for their impact on mental health. Meta is also currently facing a separate trial in Novel Mexico.

The Addiction Machine Argument

The plaintiff’s attorney, Mark Lanier, has argued that Meta and YouTube intentionally created “addiction machines” designed to exploit the brains of children. He presented internal documents, including a 2015 email from Meta CEO Mark Zuckerberg, demanding a 12% increase in “time spent” on the platform to meet business goals. This evidence supports the claim that user engagement, even at the expense of well-being, was a primary driver of platform design.

FAQ: Social Media and Mental Health

Q: Has KGM been diagnosed with social media addiction?
A: No, KGM has never received a diagnosis of social media addiction from a doctor or mental health provider.

Q: Did KGM seek help for her social media use?
A: KGM stated she didn’t raise concerns about overuse or addiction with providers as she feared being told to quit entirely.

Q: What is a bellwether trial?
A: A bellwether trial is a test case designed to gauge how a jury will respond to evidence and arguments, potentially influencing the settlement or outcome of similar lawsuits.

Q: What role did therapists play in KGM’s case?
A: Notes from KGM’s therapy sessions were presented, indicating that social media and her sense of self were “closely related.”

Did you know? YouTube intentionally targeted young users because it could “charge advertisers more” than on its YouTube Kids platform.

Pro Tip: Regularly review your own social media usage and consider setting time limits to promote a healthier relationship with these platforms.

This case is unfolding, and its implications are far-reaching. Stay informed about the latest developments and consider the impact of social media on your own life and the lives of those around you.

Want to learn more? Explore our other articles on digital wellness and the impact of technology on mental health. [Link to related article]

0 comments
0 FacebookTwitterPinterestEmail
Health

Study identifies antiviral protein IFN-γ as a potential biomarker for Long COVID fatigue

by Chief Editor
written by Chief Editor

Unlocking Long COVID: The Role of IFN-γ and the Path to Personalized Treatment

Millions worldwide continue to grapple with the debilitating effects of Long COVID, placing a significant strain on healthcare systems. Now, a groundbreaking study led by the University of Cambridge has identified the antiviral protein interferon gamma (IFN-γ) as a potential biomarker for Long COVID fatigue, offering a crucial step towards understanding – and potentially treating – this complex condition.

The Persistent Immune Response: What the Research Reveals

SARS-CoV-2 infection normally triggers the production of IFN-γ as part of the body’s immune response. Typically, this production subsides once the infection clears. Still, researchers found that in some Long COVID patients, elevated levels of IFN-γ persisted for up to 31 months, correlating with ongoing symptoms like fatigue, muscle ache, and depression. This prolonged immune activation appears to be a key factor in the development and persistence of Long COVID.

The study, published in Science Advances, followed 111 COVID-confirmed patients and 55 experiencing severe Long COVID symptoms for an extended period. Analysis of blood samples revealed that white blood cells produced IFN-γ, a pro-inflammatory molecule, which remained elevated in Long COVID sufferers. Researchers pinpointed CD8+ T cells and CD14+ monocytes as the key immune cells driving this persistent IFN-γ production.

IFN-γ as a Biomarker: A New Avenue for Diagnosis

“We have found a potential mechanism underlying Long COVID which could represent a biomarker – that is, a tell-tale signature of the condition,” explains Dr. Benjamin Krishna, co-author of the study. “We hope that this could help to pave the way to develop therapies and give some patients a firm diagnosis.” Identifying IFN-γ levels could offer a more objective way to diagnose Long COVID, moving beyond reliance on self-reported symptoms.

Vaccination and Recovery: A Promising Connection

Interestingly, the research similarly suggests a link between vaccination and symptom improvement. Researchers observed a significant decrease in IFN-γ levels after vaccination in Long COVID patients whose symptoms resolved. This suggests vaccination may help clear persistent SARS-CoV-2, reducing the inflammatory response and alleviating symptoms. However, Dr. Krishna emphasizes the need for dedicated therapies, stating, “vaccination seems to be playing a significant role [in reducing Long COVID cases], but new cases are still cropping up.”

Beyond Microclotting: A More Complete Picture

While previous research has explored microclotting as a potential cause of Long COVID, this study suggests it may not be the sole or primary driver. The findings highlight the importance of immune dysregulation, specifically the persistent IFN-γ response, in understanding the condition’s complexities.

The Future of Long COVID Research: Personalized Medicine and Pandemic Preparedness

Classifying Long COVID Subtypes

The study proposes that IFN-γ levels could be used to classify Long COVID into subtypes, enabling more personalized treatment approaches. “It’s unlikely that all the different Long COVID symptoms are caused by the same thing,” Dr. Krishna notes. “We need to differentiate between people and tailor treatments.” This shift towards personalized medicine could dramatically improve outcomes for Long COVID patients.

Preparing for Future Pandemics

Understanding the mechanisms behind Long COVID isn’t just crucial for current patients; it’s vital for preparing for future coronavirus pandemics. As Dr. Krishna points out, “Understanding what causes Long COVID now could give us a crucial head start” in mitigating the long-term effects of future outbreaks.

Frequently Asked Questions

  • What is IFN-γ? IFN-γ is an antiviral protein produced by the immune system in response to infection.
  • Is Long COVID a real condition? Yes, research increasingly confirms Long COVID as a distinct and debilitating condition affecting millions.
  • Can vaccination help with Long COVID? The study suggests vaccination may reduce IFN-γ levels and improve symptoms in some patients.
  • Is microclotting the only cause of Long COVID? No, this study indicates that persistent immune activation, specifically IFN-γ production, plays a significant role.

Pro Tip: If you are experiencing persistent symptoms after a COVID-19 infection, consult with a healthcare professional to discuss potential Long COVID diagnosis and management options.

Want to learn more about the latest advancements in Long COVID research? Explore more articles on News-Medical.net.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts